In development: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Expected publication date

Expected publication date

Guidance programme 1 selected

Guidance programme

Area of interest

Showing 21 to 30 of 293

TitleTypeExpected publication date
Aumolertinib for untreated EGFR mutation-positive non-small-cell lung cancer [ID4000]Technology appraisal guidanceTBC
Autologous chondrocyte implantation using 3D collagen matrix (novocart 3D) for treating articular cartilage defects of the knee [ID2707]Technology appraisal guidanceTBC
Avacincaptad pegol for treating geographic atrophy caused by age-related macular degeneration [ID6401]Technology appraisal guidanceTBC
Avapritinib for treating inadequately controlled moderate to severe indolent systemic mastocytosis [ID6578]Technology appraisal guidance
Avelumab for previously treated platinum-resistant ovarian cancer [ID1497]Technology appraisal guidanceTBC
Avelumab for untreated PD-L1 positive recurrent or metastatic non-small-cell lung cancer [ID1261]Technology appraisal guidanceTBC
Axatilimab for treating active chronic graft-versus-host disease after 2 or more systemic treatments in people 2 years and over [ID6570]Technology appraisal guidanceTBC
Baloxavir marboxil for influenza prophylaxis in people aged 12 and over [ID3793]Technology appraisal guidanceTBC
Baloxavir marboxil for reducing direct transmission of influenza A or B in people 5 to 64 years [ID6552]Technology appraisal guidanceTBC
Baricitinib for treating severe or very severe alopecia areata in people 6 to 17 years [ID6541]Technology appraisal guidanceTBC

Results per page

  1. 10
  2. 25
  3. 50
  4. All